Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Rises By 691.3%

SciSparc Ltd. (NASDAQ:SPRC) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 273,800 shares, an increase of 691.3% from the August 31st total of 34,600 shares. Based on an average daily trading volume, of 3,610,000 shares, the short-interest ratio is currently 0.1 days. Approximately 11.2% of the shares of the company are short sold.

Institutional Trading of SciSparc

An institutional investor recently bought a new position in SciSparc stock. Renaissance Technologies LLC bought a new stake in shares of SciSparc Ltd. (NASDAQ:SPRC) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned approximately 5.59% of SciSparc as of its most recent SEC filing. 25.06% of the stock is currently owned by institutional investors.

SciSparc Trading Up 3.8 %

SPRC stock traded up $0.01 during midday trading on Friday, reaching $0.25. 549,205 shares of the company’s stock traded hands, compared to its average volume of 1,762,128. The company has a 50-day moving average price of $0.37 and a two-hundred day moving average price of $0.99. SciSparc has a 52 week low of $0.23 and a 52 week high of $14.22.

SciSparc Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.